Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis

Código QR

Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis

ABSTRACT: Background: Comparative effectiveness of 7 glucagon-like peptide 1 (GLP-1) agents on weight loss (WL) in obesity remains unknown. Methods: We performed a systematic review, network meta-analysis (NMA) utilizing the following data sources: MEDLINE, EMBASE, Scopus, Cochrane Central and clin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kia Vosoughi, Jessica Atieh, Lehar Khanna, Katayoun Khoshbin, Larry J. Prokop, Perica Davitkov, M. Hassan Murad, Michael Camilleri
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/2b91c305c8734797ae3c417238d6663c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
por: Minara S. Shamkhalova, et al.
Publicado: (2020)

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
por: Gurung T, et al.
Publicado: (2015)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
por: Gagik R. Galstyan, et al.
Publicado: (2017)

Intermittent Use of a Short-Course Glucagon-like Peptide-1 Receptor Agonist Therapy Limits Adverse Cardiac Remodeling via Parkin-dependent Mitochondrial Turnover
por: Juliana de F. Germano, et al.
Publicado: (2020)

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
por: Marina Vladimirovna Shestakova
Publicado: (2010)

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
por: Nina A. Petunina, et al.
Publicado: (2018)

Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
por: Courtney H, et al.
Publicado: (2017)

Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
por: Levin PA, et al.
Publicado: (2017)

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
por: Teshome G, et al.
Publicado: (2020)

Glucagon-Like Peptide-1 Agonist Exendin-4 Facilitates the Extinction of Cocaine-Induced Condition Place Preference
por: Changliang Zhu, et al.
Publicado: (2021)

Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems
por: Han N, et al.
Publicado: (2021)

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
por: Marina V. Shestakova, et al.
Publicado: (2017)

Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review
por: Berlie H, et al.
Publicado: (2012)

Effects of exendin-4, a glucagon like peptide-1 receptor agonist, on neutrophil count and inflammatory cytokines in a rat model of endotoxemia
por: Yanay O, et al.
Publicado: (2015)

Travelers’ vaccines and their adverse events in Nara, Japan
por: Ogawa Taku, et al.
Publicado: (2021)

Evaluation of the Direct Costs of Managing Adverse Drug Events in all Ages and of Avoidable Adverse Drug Events in Older Adults in Japan
por: Hayato Katsuno, et al.
Publicado: (2021)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
por: Enrique Z. Fisman, et al.
Publicado: (2021)

The Mediating Processes between Depression and Cardiac Adverse Events
por: R Bagherian,, et al.
Publicado: (2011)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao Q, et al.
Publicado: (2016)

Model for glucagon secretion by pancreatic α-cells.
por: Virginia González-Vélez, et al.
Publicado: (2012)

Systemic adverse events after screening of retinopathy of prematurity with mydriatic.
por: Shumpei Obata, et al.
Publicado: (2021)

Assessment and monitoring of biologic drug adverse events in patients with psoriasis
por: Hanley T, et al.
Publicado: (2016)

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Zheng-Hang Wang, et al.
Publicado: (2018)

The dependence structure of log-fractional stable noise with analogy to fractional Gaussian noise
por: Murad S. Taqqu, et al.
Publicado: (2008)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Xiaoyin Bai, et al.
Publicado: (2021)

A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)
por: Samit Ghosal, et al.
Publicado: (2021)

Adverse events of inactivated COVID-19 vaccine in HIV-infected adults
por: Songjie Wu, et al.
Publicado: (2021)

RISK FACTORS FOR EARLY PREDICTION OF ADVERSE DRUG EVENTS RELATED TO HOSPITALIZATIONS
por: Patricia de Carvalho Mastroianni, et al.

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
por: Zoe Apalla, et al.
Publicado: (2021)

Attitudes toward metabolic adverse events among patients with schizophrenia in Japan
por: Sugawara N, et al.
Publicado: (2016)

A Deep Learning-Based Text Classification of Adverse Nursing Events
por: Wenjing Lu, et al.
Publicado: (2021)

Risk factors for early prediction of adverse drug events related to hospitalizations
por: Patricia de Carvalho MASTROIANNI, et al.
Publicado: (2016)

Vigilancia de eventos adversos a vacunas: Adverse events surveillance
por: Abarca V,Katia
Publicado: (2007)

Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003
por: Delpiano M.,Luis
Publicado: (2005)

α-cell glucokinase suppresses glucose-regulated glucagon secretion
por: Davide Basco, et al.
Publicado: (2018)

Involvement of the Catecholamine in Glucagon-Induced Thermogenesis in Duckling (Carina Moschata)
por: M. Slimani,, et al.
Publicado: (2007)

Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
por: Kedia N
Publicado: (2011)

Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
por: Ying Jing, et al.
Publicado: (2020)

Adverse events of extracorporeal ultrasound-guided high intensity focused ultrasound therapy.
por: Tinghe Yu, et al.
Publicado: (2011)

Development of instrument to report and assess causality of adverse events related to herbal medicines
por: Patrícia de Carvalho Mastroianni, et al.